In July 2026, Belenos’ partner Keymed Biosciences received Breakthrough Therapy Designation in China for BEL512, for the treatment of CRSwNP.

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and ...

The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase ...

Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...

Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, ...

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to ...

Please provide your email address to receive an email when new articles are posted on . The treatment group had reductions in FeNO 1 week after a single dose. Reductions were significant compared with ...

Patients with acute asthma exacerbations who do not suppress eosinophils after a course of oral corticosteroids (OCS) may have slower clinical recovery, according to one study. In some patients with ...

Healthy brinchial tube and constricted bronchial tube with asthma CSJ117, formulated as an engineered powder in hard capsules for delivery to the lungs via dry powder inhaler, may be the first inhaled ...

Asthma is a chronic inflammatory condition marked by an imbalance in the immune response within the airways. According to Lancet, asthma affects around 339 million people globally. While conventional ...

Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, ...